CoronaCentral
Dashboard
Trending
Epidemiology
Forecasting & Modelling
Infection Reports
Transmission
Contact Tracing
Prevalence
Prevention
Surveillance
Clinical
Clinical Reports
Risk Factors
Long Haul
Pediatrics
Medical Specialties
Recommendations
Imaging
Diagnostics
Healthcare Workers
Biology
Molecular Biology
Immunology
Model Systems & Tools
Non-human
Treatment
Therapeutics
Drug Targets
Vaccines
Clinical Trials
Medical Devices
Psychology
Policy
Health Policy
Communication
Inequality
Education
Other Articles
Reviews
Meta-analysis
Comments & Editorials
CDC Weekly Reports
Book Chapters
News
Non-medical
Retractions
Misinformation
Mentions
Drugs
Genes or Proteins
Genetic Variation
Locations
Medical Specialties
Prevention Methods
Risk Factors
Species
Symptoms
Test Types
Transmission Types
Vaccine Types
Viral Lineages
FAQs
Feedback
Select virus of interest
Vaccines
Share
Research examining the development of vaccines
Published and Preprint Papers
Filter
Export
Vaccine Types
Title
Altmetric
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
RNA vaccine
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
adenovirus vaccine
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
RNA vaccine
An mRNA Vaccine against SARS-CoV-2 - Preliminary Report.
adenovirus vaccine
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
RNA vaccine
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
RNA vaccine
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.
adenovirus vaccine
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
10
15
20
25
30